文献速递胸部肿瘤放疗

IDEAL-CRT 长期结果:等毒性剂量递增放疗联合同期化疗治疗 II/III 期非小细胞肺癌的 1/2 期试验

Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-12-03

结果显示毒性可接受,6 周方案患者总生存显著长于 5 周方案,且探索性分析中方案与 OS、PFS 显著相关。

要点

  • 6 周方案患者中位 OS 41.2 个月,5 周方案 22.1 个月。
  • 总体 ≥3 级肺炎和早期食管炎发生率分别为 3.4% 和 5.9%。

核心结论

  • IDEAL-CRT 毒性可接受,6 周方案患者生存有前景且显著长于 5 周方案患者。
  • 探索性分析中方案与 OS 和 PFS 均显著相关。

研究设计与样本

  • 患者接受等毒性个体化肿瘤放疗剂量:5 周 63 至 71 Gy 或 6 周 63 至 73 Gy,均联合同期 2 周期顺铂和长春瑞滨。

主要发现

  • 36 例和 82 例患者分别采用 5 周和 6 周方案,中位处方剂量分别为 64.5 Gy 和 67.6 Gy。
  • 总体 ≥3 级肺炎和早期食管炎发生率分别为 3.4% 和 5.9%,两方案各自相似。
  • 5 周和 6 周方案晚期 2 级食管毒性发生率分别为 11.1% 和 17.1%。
  • 6 周方案患者中 ≥4 级不良事件发生 17 例(20.7%),5 周方案患者无 ≥4 级不良事件。
  • 6 周和 5 周方案中位随访分别为 51.8 和 26.4 个月,中位 OS 分别为 41.2 和 22.1 个月,中位 PFS 分别为 21.1 和 8.0 个月。

关键数值与推荐

  • 4 例不良事件为 5 级,其中 2 例被认为与放疗相关。

临床怎么用

  • 对于 II/III 期非小细胞肺癌,等毒性个体化剂量递增同期放化疗的 6 周方案毒性可接受且生存有前景。
  • 6 周方案后联合免疫药物可能进一步延长生存,值得进一步研究。

局限性

  • OS 与方案及靶区剂量覆盖的关联为探索性分析,需谨慎解读。
  • 5 周方案随访时间较短(中位 26.4 个月),可能影响与 6 周方案的生存比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The IDEAL-CRT phase 1/2 multicenter trial of isotoxically dose-escalated concurrent chemoradiation for stage II/III non-small cell lung cancer investigated two 30-fraction schedules of 5 and 6 weeks' duration. We report toxicity, tumor response, progression-free survival (PFS), and overall survival (OS) for both schedules, with long-term follow-up for the 6-week schedule. METHODS AND MATERIALS: Patients received isotoxically individualized tumor radiation doses of 63 to 71 Gy in 5 weeks or 63 to 73 Gy in 6 weeks, delivered concurrently with 2 cycles of cisplatin and vinorelbine. Eligibility criteria were the same for both schedules. RESULTS: One-hundred twenty patients (6% stage IIB, 68% IIIA, 26% IIIB, 1% IV) were recruited from 9 UK centers, 118 starting treatment. Median prescribed doses were 64.5 and 67.6 Gy for the 36 and 82 patients treated using the 5- and 6-week schedules. Grade ≥3 pneumonitis and early esophagitis rates were 3.4% and 5.9% overall and similar for each schedule individually. Late grade 2 esophageal toxicity occurred in 11.1% and 17.1% of 5- and 6-week patients. Grade ≥4 adverse events occurred in 17 (20.7%) 6-week patients but no 5-week patients. Four adverse events were grade 5, with 2 considered radiation therapy related. After median follow-up of 51.8 and 26.4 months for the 6- and 5-week schedules, median OS was 41.2 and 22.1 months, respectively, and median PFS was 21.1 and 8.0 months. In exploratory analyses, OS was significantly associated with schedule (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.32-0.98; P = .04) and fractional clinical/internal target volume receiving ≥95% of the prescribed dose (HR, 0.88; 95% CI, 0.77-1.00; P = .05). PFS was also significantly associated with schedule (HR, 0.53; 95% CI, 0.33-0.86; P = .01). CONCLUSIONS: Toxicity in IDEAL-CRT was acceptable. Survival was promising for 6-week patients and significantly longer than for 5-week patients. Survival might be further lengthened by following the 6-week schedule with an immune agent, motivating further study of such combined optimized treatments.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Fenwick JD, Landau DB, Baker AT, et al. Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31809876. doi:10.1016/j.ijrobp.2019.11.397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。